Cogent Biosciences, Inc. (COGT) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $32.88 (-1.53%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 7, 2026 | Michael Yee | UBS | $60.00 | +82.5% |
| Nov 11, 2025 | Chris Raymond | Raymond James | $60.00 | +82.5% |
| Nov 10, 2025 | David Nierengarten | Wedbush | $38.00 | +15.6% |
| Jan 14, 2025 | Robert Burns | H.C. Wainwright | $14.00 | -57.4% |
| Sep 24, 2024 | David Lebowitz | Citigroup | $15.00 | -54.4% |
| Sep 3, 2024 | David Lebowitz | Citigroup | $13.00 | -60.5% |
| Sep 3, 2024 | Robert Burns | H.C. Wainwright | $17.00 | -48.3% |
| Mar 30, 2024 | Kelly Shi | Jefferies | $20.00 | -39.2% |
| Jun 17, 2022 | Chris Raymond | Raymond James | $22.00 | -33.1% |
| Jun 10, 2022 | Christopher Liu | Leerink Partners | $15.00 | -54.4% |
Top Analysts Covering COGT
COGT vs Sector & Market
| Metric | COGT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 5 | 8 | 18 |
| Target Upside | +55.1% | +16187.2% | +19.5% |
| P/E Ratio | -7.47 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $2M | $2M | $2M | 1 |
| 2026-12-31 | $16M | $16M | $16M | 1 |
| 2027-03-31 | $54M | $54M | $54M | 1 |
| 2027-06-30 | $86M | $86M | $86M | 1 |
| 2027-09-30 | $127M | $127M | $127M | 1 |
| 2027-12-31 | $172M | $172M | $172M | 1 |
| 2028-12-31 | $764M | $764M | $764M | 9 |
| 2029-12-31 | $422M | $1.31B | $2.84B | 4 |
| 2030-12-31 | $564M | $1.75B | $3.79B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.56 | $-0.56 | $-0.56 | 3 |
| 2026-12-31 | $-0.51 | $-0.51 | $-0.51 | 3 |
| 2027-03-31 | $-0.24 | $-0.24 | $-0.24 | 3 |
| 2027-06-30 | $-0.13 | $-0.13 | $-0.13 | 2 |
| 2027-09-30 | $0.03 | $0.03 | $0.03 | 2 |
| 2027-12-31 | $0.20 | $0.20 | $0.20 | 2 |
| 2028-12-31 | $0.23 | $1.05 | $2.35 | 8 |
| 2029-12-31 | $0.37 | $3.07 | $7.75 | 6 |
| 2030-12-31 | $0.57 | $4.76 | $12.01 | 6 |
Frequently Asked Questions
What is the analyst consensus for COGT?
The consensus among 5 analysts covering Cogent Biosciences, Inc. (COGT) is Buy with an average price target of $46.75.
What is the highest price target for COGT?
The highest price target for COGT is $60.00, set by Michael Yee at UBS on 2026-01-07.
What is the lowest price target for COGT?
The lowest price target for COGT is $13.00, set by David Lebowitz at Citigroup on 2024-09-03.
How many analysts cover COGT?
5 analysts have issued ratings for Cogent Biosciences, Inc. in the past 12 months.
Is COGT a buy or sell right now?
Based on 5 analyst ratings, COGT has a consensus rating of Buy (2.00/5) with a +55.1% upside to the consensus target of $46.75.
What are the earnings estimates for COGT?
Analysts estimate COGT will report EPS of $-0.56 for the period ending 2026-09-30, with revenue estimated at $2M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.